

COLO-PREVENT

A platform for developing COLOrectal cancer PREVENTion therapies

Welcome! We are excited to launch the first of our monthly newsletters. Here we will provide updates and progress of the trial.

SITE SET UP PROGRESS



- We are in the process of setting up several sites and over the next 18 months we anticipate approximately 60 Trusts will be open for recruitment.
- In order to meet the funding requirements set by Cancer Research UK, we require your completed Expression of Interest (EOI) forms as soon as possible. **Do not delay!** This will also enable us to sufficiently forward plan and organise for your site initiation.
- Please get in touch if you require any assistance with your EOI.
- **King's Mill Hospital: FIRST SITE to OPEN for COLO-PREVENT.**
- **5 further sites have received Sponsor Green light:** Dorset County Hospital, South Tyneside District Hospital, Royal Cornwall Hospital, Norfolk & Norwich University Hospital, Northumbria Healthcare NHS Foundation Trust.



KEY ACHIEVEMENTS

- Successfully navigated the new combined review system and obtained the **regulatory approval on 23rd June 2022.**
- Successfully delivered **two PI drop-in sessions** in July 2022
- **6** Site Initiation Visits
- **6 Sites Open** (December 2022 and February 2023)
- **18** Participants **Screened** at King's Mill Hospital
- **2** Participants **Screened** at Dorset County Hospital
- Dr Ajay Verma presented COLO-PREVENT at the latest Gastroenterology National Speciality Group Leads Meeting
- Effectively worked with the Manufacturer to develop two doses of Resveratrol capsules (& matching Placebo) from the API (Active Pharmaceutical Ingredient).
- Successfully navigated changes in regulations in importing API following Brexit.



NEXT STEPS

- Coloprevent website now live. Visit www.coloprevent.co.uk for latest updates
- First **COLO-PREVENT Launch meeting** to be held on the **24th of March 2023**. **Watch this space** for more info on the venue and how to join (remote/face to face).
- Manufacturing of Resveratrol and Placebo capsules started at the end of **February 2023**

UK SITES

So far a number of Trusts across the UK have either expressed interest or completed their EOI forms.

Thank you!

Thank you!



PROTOCOL CLARIFICATION

Fit Test: Faecal sample is being collected for Research purposes on a FIT Kit for Microbiome Analysis. (Sites will not receive results for this). This will be clarified in the next version of the Protocol

Meet the COLO-PREVENT Team



Professor Anne Thomas
Chief Investigator



Nafisa Boota
Senior Trial Manager



Professor Karen Brown
Lead Applicant on Grant



Claire Smith
Clinical Trial Coordinator



Professor Mark Hull
Joint lead applicant and CI for seAFood.



Deepthi Krovi
Clinical Trial Administrator



Dr Ajay Verma
Co-Investigator

Please give us feedback and get in touch with the Trial Team at
coloprevent@leicester.ac.uk

Don't forget to follow us on Twitter for the latest updates on the trial !



@coloprevent



**CANCER
RESEARCH
UK**